All In Biotech

Drug Trial Radar · NCT05728944

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

229

Actual

Start

Mar 6, 2023

Primary completion

Dec 14, 2023

Study completion Jan 24, 2024

Sponsor

Lead sponsor
LENZ Therapeutics, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia

Conditions

  • Presbyopia
  • Near Vision
  • Refractive Error
  • Eye Diseases

Interventions

  • Aceclidine+Brimonidine combination ophthalmic solutionDrug

    Aceclidine + Brimonidine combination ophthalmic solution

  • Aceclidine ophthalmic solutionDrug

    Aceclidine ophthalmic solution

  • VehicleDrug

    Proprietary vehicle ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 3 hours post-treatment in the study eye on Day 1

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Site #209

    Dothan, Alabama

  • Site #216

    Scottsdale, Arizona

  • Site #220

    Glendale, California

  • Site #214

    La Jolla, California

  • Site #203

    Newport Beach, California

  • Site #204

    Danbury, Connecticut

  • Site #205

    Crystal River, Florida

  • Site #218

    Northbrook, Illinois

  • Site #211

    Louisville, Kentucky

  • Site #208

    St Louis, Missouri

  • Site #215

    Bozeman, Montana

  • Site #219

    Dover, New Jersey

  • Site #221

    Rochester, New York

  • Site #212

    West Fargo, North Dakota

  • Site #207

    Powell, Ohio

  • Site #213

    Eugene, Oregon

  • Site #217

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.